60 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
Rank Status Study
21 Recruiting Cohort of Patients Infected by an Arbovirus
Conditions: Fever;   Dengue;   Chikungunya;   Zika
Interventions: Other: biological sample collection;   Other: quality of life questionnaire EuroQol®;   Other: Health Assessment Questionnaire - MDHAQ and RAPID3
22 Unknown  Prospective Study of Infant Dengue
Condition: Dengue
Intervention:
23 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
24 Not yet recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
25 Not yet recruiting Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults
Conditions: Dengue;   Transaminitis
Interventions: Drug: Paracetamol;   Drug: Placebo
26 Recruiting The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Conditions: Zika Virus Disease (Disorder);   Dengue;   Chikungunya
Intervention:
27 Recruiting Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Conditions: Zika Virus;   Dengue Virus;   Chikungunya Virus Infections
Intervention:
28 Recruiting This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia
Condition: Dengue
Intervention: Procedure: Blood sample collection
29 Recruiting A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
Condition: Yellow Fever
Interventions: Biological: MVA Smallpox Vaccine;   Biological: YF Vax 17D Strain;   Drug: ISA-720;   Other: Placebo;   Biological: MVA-BN Yellow Fever Vaccine
30 Not yet recruiting Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Condition: Malaria Vaccines
Interventions: Dietary Supplement: Vitamin A;   Biological: Candidate Plasmodium falciparum malaria vaccine;   Biological: MR-Vac;   Biological: Stamaril
31 Recruiting Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: rDEN3∆30;   Biological: Placebo
32 Not yet recruiting Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh
Condition: Dengue
Interventions: Biological: TV005 vaccine;   Biological: Placebo
33 Recruiting Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou
Condition: Dengue Fever
Intervention:
34 Recruiting The Use of Biomarkers in Predicting Dengue Outcome
Condition: Dengue
Intervention:
35 Recruiting A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
Condition: Dengue
Intervention: Procedure: Blood sample collection
36 Not yet recruiting Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore
Condition: Dengue Fever
Interventions: Drug: Celgosivir;   Drug: Modipafant 50mg;   Drug: Placebo;   Drug: Modipafant 100mg
37 Recruiting Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
Conditions: Yellow Fever Vaccine;   Immunity
Intervention: Biological: yellow fever vaccine
38 Not yet recruiting Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis
Condition: Dengue
Intervention: Device: SaniSal Oral Fluid Collector
39 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
40 Recruiting Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore
Condition: Dengue Fever
Interventions: Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV);   Biological: Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years